Gloria Lee

发表

Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis.

W. H. Benner, R. Krauss, W. Salameh, 2008, Clinical chemistry.

Expression of the ATP-binding Cassette Membrane Transporter, ABCG2, in Human and Rodent Brain Microvessel Endothelial and Glial Cell Culture Systems

R. Bendayan, A. Prat, Gloria Lee, 2007, Pharmaceutical Research.

Functional Expression and Localization of P-glycoprotein in the Central Nervous System: Relevance to the Pathogenesis and Treatment of Neurological Disorders

R. Bendayan, Gloria Lee, Reina Bendayan, 2004, Pharmaceutical Research.

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Mitch Dowsett, Gerhardt Attard, Johann S de Bono, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Time-Dependent Instability of Cardiac Troponins in Human Plasma Spiked with NIST Reference Material

W. H. Benner, R. Krauss, W. Salameh, 2008 .

Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin’s lymphoma: phase I safety and efficacy

K. Tobinai, I. Choi, K. Ando, 2022, Japanese journal of clinical oncology.

Crossover pharmacokinetics (PK) study to assess oral administration of abiraterone acetate capsule and tablet formulations in fasted and fed states in patients with prostate cancer

Robin L. Jones, F. Kabbinavar, F. Raynaud, 2008 .

Acetaminophen selectively suppresses peripheral prostaglandin E2 release and increases COX-2 gene expression in a clinical model of acute inflammation

Yun‐Sil Lee, R. Dionne, Hyungsuk Kim, 2007, PAIN.

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.

D. Dearnaley, C. Parker, H. Scher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

P. Kantoff, E. Small, J. Rosenberg, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

M. Dowsett, D. Dearnaley, C. Parker, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Functional expression and localization of P‐glycoprotein at the blood brain barrier

R. Bendayan, Gloria Lee, Reina Bendayan, 2002, Microscopy research and technique.

Phase I study of continuous oral dosing of an irreversible CYP17 inhibitor, abiraterone (A), in castration refractory prostate cancer (CRPC) patients (p) incorporating the evaluation of androgens and steroid metabolites in plasma and tumor

M. Dowsett, D. Dearnaley, C. Parker, 2007 .

Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC)

M. Dowsett, D. Dearnaley, C. Parker, 2008 .

Involvement of P-Glycoprotein in the Transport of Saquinavir and Indinavir in Rat Brain Microvessel Endothelial and Microglia Cell Lines

R. Bendayan, S. Dallas, P. Ronaldson, 2004, Pharmaceutical Research.

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

M. Dowsett, D. Dearnaley, C. Parker, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.

D. Dearnaley, C. Parker, H. Scher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.